{"name":"IDEAYA Biosciences, Inc.","slug":"ideaya","ticker":"IDYA","exchange":"NASDAQ","domain":"ideayabio.com","description":"IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in","hq":"South San Francisco, CA","founded":2017,"employees":"145","ceo":"Yujiro S. Hata","sector":"Oncology Biotech","stockPrice":28.76,"stockChange":-0.14,"stockChangePercent":-0.48,"marketCap":"$2.5B","metrics":{"revenue":225270000,"revenueGrowth":0,"grossMargin":-50.7,"rdSpend":0,"netIncome":-140059008,"cash":671201024,"dividendYield":0,"peRatio":-7.8,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-22","type":"regulatory","headline":"IDEAYA Biosciences Announces FDA Clearance of Investigational New Drug (IND) Application for IDE196","summary":"IDEAYA Biosciences announced that the FDA has cleared the IND application for IDE196, enabling the company to proceed with clinical trials.","drugName":"IDE196","sentiment":"positive"},{"date":"2022-11-14","type":"earnings","headline":"IDEAYA Biosciences Reports Third Quarter 2022 Financial Results","summary":"IDEAYA Biosciences reported its third-quarter 2022 financial results, highlighting progress in its pipeline and financial performance.","drugName":"","sentiment":"neutral"},{"date":"2022-08-09","type":"deal","headline":"IDEAYA Biosciences Enters into Collaboration Agreement with Merck KGaA, Darmstadt, Germany","summary":"IDEAYA Biosciences entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, to develop and commercialize IDE196 in combination with Merck's KEYTRUDA.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNWjczTHRrN09LaS1ORW1Mb09CSkR6dEREWVp6UGgxbDNSVDkzdnBTSjR4WXB4VHJyUG9jS0lZTnBpX0FZNUR3MEFlN3JIckNtOXJMZVNtdVBDR0lWdVE1UEk5Zk5qek9zX0djUGR5Ym5oYmJBMDlVRnhuajh5REk1SmhBaXNaamo0SEFDQTlNZzJ4RmZseTVGZWxRSDg2QzBYTVcxbXI4emFpV0lUOUtQbzB0M05MdkEzMURUTmRMU1VZY1JSRDE1MW1qWS1uMTBONzdjRENzWFB6Y0dqLXVibHR2SG4?oc=5","date":"2026-04-07","type":"trial","source":"BioPharma APAC","summary":"IDEAYA Biosciences Advances IDE574 Into Phase 1 As First Patient Enrolled For KAT6 And KAT7 Dual Inhibitor - BioPharma APAC","headline":"IDEAYA Biosciences Advances IDE574 Into Phase 1 As First Patient Enrolled For KAT6 And KAT7 Dual Inhibitor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQUUUzNkM5a09aY3lpQ3hkaDVVay1XdTQ2ZzYtcHM0Z0xiZTZkVTNkNzFZQXhERUNaUU1keDNIN3BuNl9lME13V1ZaZTl2a2JtOHNSa19TdllTWXNYMjBBM0tkR2Vic2JXNVRTeHFESkNTVy1LRkYxbm40V1BFTzVzVzRUMXlJd2x2ZW5PU1RqNTk5V3ZDR2JvZnZZdlRsRFE5ZVBraG56WnNLYzRzc0k0UkRHcVVOUklYeWdZU2tpcw?oc=5","date":"2026-02-27","type":"trial","source":"Stock Titan","summary":"New tumor-targeting drug starts first human trial, triggers $5M payout - Stock Titan","headline":"New tumor-targeting drug starts first human trial, triggers $5M payout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPQWRnOU1udGdVTjVwSzlxTTgxRFk3Sm5uUWZWd2Q3T28xQURmUUlGaXBjN2Rsc0lQTlJoamR1NzQ0czRKdUhFM3dDUlRpaXJsX1gxeThQNE5oLU1nUWVkOUNSSzc5c090MWcxS2ZjR0JyOEVtWUxScFpmTFJuUEE1ODFHc1RrTzByNTNhcjNwOGNfZU0?oc=5","date":"2025-12-09","type":"pipeline","source":"The Pharma Letter","summary":"GSK ends synthetic lethality pact with Ideaya - The Pharma Letter","headline":"GSK ends synthetic lethality pact with Ideaya","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNS3hrVEpQM0hZbzlZU2Nra3ZhSTUzUEsxUy1yLXcwTE9MM2pXTDFCTkU0OU1CY2xmUm9WODhFWUhFTFlJU18yM1pCVjFQOTByaVZVaWc0ZXh4UHNRZ2xjeDVKdHFDdmlNWUptZ0NtWkRuVFo4TkNjazMzR1d2MnVHVU55dkRnSm9qQUdJRFBQMWo3ZWpKYjl5b0IxVXIzUjZzY0tHMzRRNHVfTHhzWFNsS3FvNHdQczJ1akRCbVIyZ1ZnQzlGUnpZTE1GWTFQdTQ2QWhkV0ZNaE9GbERFamN3Wmt4dFE?oc=5","date":"2025-12-08","type":"regulatory","source":"BioPharma APAC","summary":"Biocytogen Announces FDA IND Clearance for IDE034 Bispecific B7H3 PTK7 ADC Licensed to IDEAYA Biosciences - BioPharma APAC","headline":"Biocytogen Announces FDA IND Clearance for IDE034 Bispecific B7H3 PTK7 ADC Licensed to IDEAYA Biosciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPSjJWV0F4Wmp3VVJvclBwaF82azBobzIwNFlwTXByX1hpaWxUY1pnV09XVHItYmdmX1I4MzYxZnJBOFZqRXdKdWxaXzhnQmNYSm9taEpJa0hudXZXS3FPNXBna2xXTmZCVnVzalBlUnBEMGtIeEdSWDVRVG5zTDZnY2p2cDNLWEpEdkNzc1dkaVltOHM?oc=5","date":"2025-12-08","type":"deal","source":"BioSpace","summary":"GSK Cuts Five-Year-Old Cancer Collaboration With Ideaya - BioSpace","headline":"GSK Cuts Five-Year-Old Cancer Collaboration With Ideaya","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxNTzFnMThZTTJKbG1vTjNOZnI0UmZTc0xtUVZudmJJLWtiRnRwcFVXSTNHZXMtQUJUM202UlltOXRNN1M0TkNpeS1GdkxzR0RMZ2JxVmZydkhBbGJVbXVxRFE0UTQwOXR1eUdRZUgtaXlkcW1rOEZKdGZhWmJLRTZyWHZSeHRqeTlBbTljc0lmXzc5TWlKbE9zTUVuS24zZXJOSDhWRHJudE1BNlRwd0ZrcFEtUWtKZkJlQk85RXg5Y1BxRW9Vcm44bzhLOUkzdXgxWUlZNDFrNA?oc=5","date":"2025-12-04","type":"regulatory","source":"Business Wire","summary":"IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance - Business Wire","headline":"IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNOVFLMlBQWWVZUk5kTHFLX3ZNZ2g5dURBMzdqRVduOUpmZGpwZFZXSDNRTDVWdHpaNHRyb2NtQlpKWkMwbnVEMVNPUFRsZDc4WmZvazFOTzRSN1ZhQlVLaDRCY2lTOGl1VzZRYWZhTmk5VGttSEdUZmJXdkNpRUl3bVh2ZUVzMlN4ZWdhVHdrNXd4bnE2RmJOYWpvSVl6Um9nRlBiVDJ2UWVUQ1pJbVh0LWhTT0UxZw?oc=5","date":"2025-11-25","type":"pipeline","source":"Seeking Alpha","summary":"Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away (IDYA) - Seeking Alpha","headline":"Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away (IDYA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wJBVV95cUxQSFhGOXpONXdBQjdNQ2ZXUTdnY1lYZklJQW1SRzlBV2Rva0pQRVFPQWhvQzJYUktqT1dfMTVGNG8zeEJ6cHR5QmpONlhqdjlFUXJtck5ZaHZTVUV3X3Fhc2Vna3VaR2stNTg4cXlZbGwzRXp3VnBTT3JRLXh1U0g4OW84TkxpNTFNOWRRLUF5TFQ1MXlwbUgxUm9sd214MkI5d0ltN0tsNU44U2ZQOFVTNGpDbloxVkk0U1ZSMXZ5ZzZBaGZiYWIxLVJJRFczRUtxNk9mWi0xSUNzZlNTamZrVldqYlR1REtYOGNJU2NYU1Ric2htaDJQX2ZsbkZHakdka2JrV1BOc3RDX0diVjFDR1ozYzFkc3BkUFpNenV4TzJYWTc5Tl9ONVhBUDhTbUpqcldtRWhlVXc3Vjh2Mi1TbFBrY0E2Nmdydll3OU12UzUyQi1ZTVR5NDhrMTRxT3VFQldaOTQ4UWZ3MmVMdVJHZFJWejFUV3c?oc=5","date":"2025-09-07","type":"trial","source":"PR Newswire","summary":"IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lun","headline":"IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DL","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOTGx0YlJlT2VDWk85Y3doVkVDd09VTF92WDVGdkxrY3VQamwxd01JUnFWaDZVWFJmSnhNYWlTOFJpRms4QnNETzV4a21IT2xwT1pfa3dtc1k5SzFEN1NQcDhkam0xTUppWkdsSzV6bXN0ZTRvNzFkUWc3ODgxa3FTSFhaS21fTU0?oc=5","date":"2025-09-02","type":"pipeline","source":"Servier","summary":"Promising Uveal Melanoma Treatment - Servier","headline":"Promising Uveal Melanoma Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxOUlBwZG9QOUVDWlZ3MFRWZ0tHQVJVN0RVLTY1THg1clFHS04wbTRVaXRHaDBHZkthSUw1Zmd2MUVJZkp1ZTEzSi0wMXk1SGFaTEF0SHBIa0NOdlJoVFBPbDUxWFhXSXZ3SW1DQmdETXBHQ0F6R0c3bzNSREZha192TUlVWkNZd2pBMTF6azNRNGJxZHpQakVoUXVIMEtvMlBqaEdTeWQ5dmtXeWhrNHFWa2wtRFlGYzlOQVIzOVp3eW51NTVweGdrVDFFYWd0LVd3VWlWbkdJMlY1ak9GMUNLa2VvajU4YmNIb3E3NUszY0VGQVZvNi1KWi1QcWZwajdJa1RyZDln?oc=5","date":"2025-09-02","type":"deal","source":"PR Newswire","summary":"Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide - PR Newswire","headline":"Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wJBVV95cUxOMHAtNnZiWWdmODlWMVh5OUthTVd6YWlFMi1iMzVSN0Y2NWdZcUc5dzhLSC1mMFB3QXZPMS02SE9xSTg1ckpwSGdiZjExb2otQ1FSc1o2Qk51bkE3OGtLV3lfRXJfUTJ0UzlRcUplaGxkVThiZ2NXZ21UUk9sTlBxcks0dFpZU0poMWZOeHlldEJ3NFpLZHpnZWY0LUtqMmlzYnA0SHdrU0FkVEFyTW80ZVFGenFHN2hiaktsczVjNmNrSlB4YXVIa0FWUnQySXdMSTB0NEJQVmgyQUxRU1ZyMkNiRTI2TEx2eVhmd2w1MmExUWhiR3JGSkJmdzdOdFM1Rk14VWZ4ZkZhb01Ya1AtbnlXSVVvdnRWaTdRR0R1SHk0OF9JUXZ1NVBfU1JYUmZvQ1hURW1oRXg5QUhiZXV4V2JBTDF2NFJPVGF0cm1RTGNTRVZ1c1Bj?oc=5","date":"2025-07-22","type":"pipeline","source":"PR Newswire","summary":"IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC - PR Newswire","headline":"IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNeF9EOUY2bTF6cmxCU3VlUUJIZ0JkNnB5WGdmc3NVZC1fWUNBdWVwM254bHpDaURKaV9INUdXeV93NFNMOXZxMHZETEJ1Tzl3QjRBVnpLeTdwUWxpY3RiWE9Na2g0cmZ4RS16LVZVRVZSVW85YnNIaGU0RUp6OWVnMXRBLTdQbVlqTFZlWVJpeHdzcm85dHgxR2d3?oc=5","date":"2025-04-02","type":"pipeline","source":"Seeking Alpha","summary":"Why Ideaya Biosciences Is Down Despite Many Positives (NASDAQ:IDYA) - Seeking Alpha","headline":"Why Ideaya Biosciences Is Down Despite Many Positives (NASDAQ:IDYA)","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Oncology"],"financials":{"source":"yahoo_finance","revenue":218710000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":218710000},{"period":"2024-12-31","value":7000000},{"period":"2023-12-31","value":23385000},{"period":"2022-12-31","value":50931000}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":314704000,"rdSpendHistory":[{"period":"2025-12-31","value":314704000},{"period":"2024-12-31","value":294673000},{"period":"2023-12-31","value":129508000},{"period":"2022-12-31","value":89536000}],"sgaSpend":63319000,"operatingIncome":-159313000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-159313000},{"period":"2024-12-31","value":-326975000},{"period":"2023-12-31","value":-134429000},{"period":"2022-12-31","value":-62502000}],"netIncome":-113698000,"netIncomeHistory":[{"period":"2025-12-31","value":-113698000},{"period":"2024-12-31","value":-274477000},{"period":"2023-12-31","value":-112961000},{"period":"2022-12-31","value":-58655000}],"eps":-3.36,"epsHistory":[{"period":"2024-12-31","value":-3.36},{"period":"2023-12-31","value":-1.96},{"period":"2022-12-31","value":-1.42},{"period":"2021-12-31","value":-1.41}],"cash":112825000,"cashHistory":[{"period":"2025-12-31","value":112825000},{"period":"2024-12-31","value":84378000},{"period":"2023-12-31","value":157018000},{"period":"2022-12-31","value":68632000}],"totalAssets":1109324000,"totalLiabilities":86390000,"totalDebt":27914000,"equity":1022934000,"operatingCashflow":-71098000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-71098000},{"period":"2024-12-31","value":-247584000},{"period":"2023-12-31","value":-115224000},{"period":"2022-12-31","value":-87175000}],"capex":-2368000,"capexHistory":[{"period":"2025-12-31","value":-2368000},{"period":"2024-12-31","value":-3857000},{"period":"2023-12-31","value":-2368000},{"period":"2022-12-31","value":-3443000}],"freeCashflow":-73466000,"dividendsPaid":null,"buybacks":null,"employees":145,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2026-03-31","revenue":null,"epsBasic":-1.11,"netIncome":null,"rdExpense":null,"epsDiluted":-1.11,"grossProfit":null,"operatingIncome":null},{"sga":18847000,"ebit":-94570000,"ebitda":-93373000,"period":"2025-12-31","revenue":10876000,"epsBasic":-0.94,"netIncome":-83273000,"rdExpense":86599000,"epsDiluted":-0.94,"grossProfit":null,"operatingIncome":-94570000},{"sga":16389000,"ebit":108452000,"ebitda":109482000,"period":"2025-09-30","revenue":207834000,"epsBasic":1.35,"netIncome":119244000,"rdExpense":82993000,"epsDiluted":1.33,"grossProfit":null,"operatingIncome":108452000},{"sga":14580000,"ebit":-88806000,"ebitda":-87573000,"period":"2025-06-30","revenue":0,"epsBasic":-0.88,"netIncome":-77491000,"rdExpense":74226000,"epsDiluted":-0.88,"grossProfit":null,"operatingIncome":-88806000},{"sga":13503000,"ebit":-84389000,"ebitda":-83256000,"period":"2025-03-31","revenue":0,"epsBasic":-0.82,"netIncome":-71405000,"rdExpense":70886000,"epsDiluted":-0.82,"grossProfit":null,"operatingIncome":-84389000},{"sga":10955000,"ebit":-144138000,"ebitda":-143495000,"period":"2024-12-31","revenue":7000000,"epsBasic":null,"netIncome":-130312000,"rdExpense":140183000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-144138000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":28.76,"previousClose":28.9,"fiftyTwoWeekHigh":39.28,"fiftyTwoWeekLow":16.9,"fiftyTwoWeekRange":"16.9 - 39.28","fiftyDayAverage":31.49,"twoHundredDayAverage":30.61,"beta":-0.04,"enterpriseValue":1896579584,"forwardPE":-7.8,"priceToBook":2.47,"priceToSales":11.22,"enterpriseToRevenue":8.42,"enterpriseToEbitda":-10.5,"pegRatio":0,"ebitda":-180680000,"ebitdaMargin":-80.2,"freeCashflow":-57254500,"operatingCashflow":-85926000,"totalDebt":28600000,"debtToEquity":3.1,"currentRatio":10.74,"returnOnAssets":-10.8,"returnOnEquity":-14.3,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":16,"targetMeanPrice":52.75,"targetHighPrice":81,"targetLowPrice":36,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.4,"institutionHeldPercent":111.1,"sharesOutstanding":87860920,"floatShares":87007790,"sharesShort":11705770,"shortRatio":7.15,"shortPercentOfFloat":13.3,"epsTrailing":-1.57,"epsForward":-3.7,"revenuePerShare":2.54,"bookValue":11.65,"officers":[{"age":51,"name":"Mr. Yujiro S. Hata","title":"Founder, President, CEO & Director"},{"age":50,"name":"Dr. Joshua  Bleharski Ph.D.","title":"Chief Financial Officer"},{"age":60,"name":"Dr. Michael A. White Ph.D.","title":"Chief Scientific Officer"},{"age":61,"name":"Mr. Douglas B. Snyder","title":"Chief Legal Officer"},{"age":58,"name":"Dr. Darrin M. Beaupre M.D., Ph.D.","title":"Chief Medical Officer"},{"age":null,"name":"Dr. Paul A. Barsanti Ph.D.","title":"Chief Technology Officer"},{"age":null,"name":"Ms. Francine  Zelaya","title":"Senior VP & Head of Human Resources"},{"age":null,"name":"Mr. Mick  O'Quigley","title":"Senior Vice President of Medical Writing & Project Management"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.ideayabio.com","phone":"650 443 6209"}}